Prof Peter Schmid presents data from the KEYNOTE-522 trial during a press conference at the 2019 ESMO congress.
This was a phase III trial looking at immunotherapy added to chemotherapy in early triple negative breast cancer.
Watch Prof Schmid's interview with ecancer here.
Read more about the study here.